Shawn C. Owen Research Group – Utah
Complementation Dependent Enzyme Prodrug Therapy Enables Targeted Activation of Prodrug on HER2-Positive Cancer Cells
https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.2c00394
Conjugation of collagen-hybridizing peptides (CHPs) to antibody fragments can improve treatment localization to sites of denatured collagen, potentially limiting on-target effects. Check it out!
Congratulations to Keith Arlotta for receiving funding through the University of Utah Graduate School!
In-depth review of the current state of therapeutic anti-cancer antibodies and antibody derivatives. This review acts as a guide, detailing the effects of specific modifications on antibody function, stability, and half-life.
https://wires.onlinelibrary.wiley.com/doi/full/10.1002/wnan.1556
Congrats to Sam Hatch for receiving funding through the University of Utah Undergraduate Research Opportunity Program.
A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays. Scientific Reports (2017) 7:8186
Congratulations to Sun Jin Kim (bottom right) as one of four graduate students to receive a Skaggs Research Fellowship.
Much thanks to the College of Pharmacy and the ALSAM Foundation.
University of Utah researchers have won six of the 20 University Technology Acceleration Grants (UTAG), a program that provides crucial funds to accelerate university-developed technologies from the idea stage to the market. The group is the first round of UTAG winners, funded by the Utah Science Technology and Research (USTAR) initiative.
Among the U’s winners are biochemist Danny Chou, bioinformatician Alistair Ward and pharmaceutical chemist Shawn Owen.